Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody

Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody

To define the efficacy of a single dose of 375 mg/m 2 rituximab for DSA-positive patients with 2000 ≤ MFI 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2020-07, Vol.55 (7), p.1326-1336
Hauptverfasser: Chang, Ying-Jun, Xu, Lan-Ping, Wang, Yu, Zhang, Xiao-Hui, Chen, Huan, Chen, Yu-Hong, Wang, Feng-Rong, Han, Wei, Sun, Yu-Qian, Yan, Chen-Hua, Tang, Fei-Fei, Huo, Ming-Rui, Zhao, Xiang-Yu, Mo, Xiao-Dong, Liu, Kai-Yan, Huang, Xiao-Jun
Format: Artikel
Sprache:eng
Schlagworte:
631/250/1854/2812
631/250/1904
Antibodies
Antithymocyte globulin
Bone marrow
Cell Biology
Desensitization
Hematology
Histocompatibility antigen HLA
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Monoclonal antibodies
Patients
Public Health
Rituximab
Stem cell research
Stem cell transplantation
Stem Cells
Transplantation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To define the efficacy of a single dose of 375 mg/m 2 rituximab for DSA-positive patients with 2000 ≤ MFI 
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-0928-z